FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma

Targeting Bruton tyrosine kinase (BTK) by ibrutinib is an effective treatment for patients with relapsed/refractory mantle cell lymphoma (MCL). However, both primary and acquired resistance to ibrutinib have developed in a significant number of these patients. A combinatory strategy targeting multip...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncogene
Huvudupphovsmän: Li, Y, Bouchlaka, MN, Wolff, J, Grindle, KM, Lu, L, Qian, S, Zhong, X, Pflum, N, Jobin, P, Kahl, BS, Eickhoff, JC, Wuerzberger-Davis, SM, Miyamoto, S, Thomas, CJ, Yang, DT, Capitini, CM, Rui, L
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5102814/
https://ncbi.nlm.nih.gov/pubmed/27157620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2016.155
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk